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INTRODUCTION
The EU Drugs Strategy 2021-2025 (hereinafter referred to as ‘the Strategy’) provides the overarching political framework 
and priorities for the European Union’s drugs policy for the period 2021-2025. The framework, aim and objectives of the 
Strategy serve as the basis for the EU Drugs Action Plan from 2021 to 2025 (hereinafter referred to as ‘the Action Plan’).
The Strategy aims to protect and improve the well-being of society and of the individual, to protect and promote public 
health, to offer a high level of security and well-being for the general public and to increase health literacy. The Strategy 
takes an evidence-based, integrated, balanced and multidisciplinary approach to the drugs phenomenon at national, EU 
and international level. It also incorporates a gender equality and health equity perspective.
The Action Plan pursues the aims and objectives of, follows the approach of, and builds on the same documents and 
information as the Strategy. The Action Plan is based on the principles, values and legal provisions which lie at the basis of 
the Strategy. In implementing the Strategy, the Action Plan addresses the existing and evolving challenges of the drugs 
phenomenon, taking on board the lessons learned from the COVID-19 pandemic and taking a future-oriented approach to 
anticipate challenges.
The Action Plan sets out the actions to be implemented to achieve the eleven strategic priorities of the Strategy. Actions are 
set out under the three policy areas of the Strategy:
— Drug supply reduction: enhancing security,
— Drug demand reduction: prevention, treatment and care services, and
— Addressing drug-related harm
and the three cross-cutting themes of the Strategy:
— International cooperation,
— Research, innovation and foresight and
— Coordination, governance and implementation.
By 2025, the priorities and actions in the field of illicit drugs, coordinated through the Strategy and implemented through 
the Action Plan, should have had an overall impact on key aspects of the EU drug situation. The coherent, effective and 
efficient implementation of measures should both ensure a high level of human health protection, social stability and 
security, and contribute to awareness raising. Any potential unintended negative consequences associated with the 
implementation of the actions should be minimised, and human rights and sustainable development promoted.
In drawing up the actions, account was taken of the need to be evidence-based, scientifically sound, realistic, time-bound 
and measurable with a clear EU relevance and added value.
The Action Plan aligns strategic priorities and actions, with a specific timetable to be developed, a list of responsible parties 
and a set of indicators based on the existing reporting mechanisms. These do not involve an additional reporting burden. 
They facilitate the measurement of the overall effectiveness of the Action Plan.
The Commission, taking into account information provided by the Member States and the EEAS, and available from the 
EMCDDA, Europol and other relevant EU bodies, as well as from civil society, will monitor the implementation of the 
Strategy and the Action Plan, in close cooperation with the Presidency and the Horizontal Working Party on Drugs (HDG), 
and will initiate an overall external evaluation of the implementation of the Strategy and of the Action Plan.
The results of this evaluation will be made available to the European Parliament and to the Council as soon as they are 
available, and at the latest by 31 March 2025, in order to be discussed in the relevant fora and in particular in the HDG. 
These discussions will form the basis for the definition of the future development of EU drugs policy and the following 
cycle of the EU Drugs Strategy and Action Plan to be approved by the Council.
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I - DRUG SUPPLY REDUCTION : ENHANCING SECURITY
Strategic priority 1: Disrupt and dismantle high-risk drug-related organised crime groups operating in, originating in or targeting the EU Member States; address links with other security threats and 
improve crime prevention
Action Priority area Timetable Responsible party (1)
Action 1
Further enhance the EMPACT (European Multidisciplinary Platform Against 
Criminal Threats) (i) on the basis of its 2020 independent evaluation and by 
taking into account the EU SOCTA 2021; (ii) on the basis of the findings 
and recommendations from the annual European Drug Reports by the 
EMCDDA and the EU Drug Markets Report by the EMCDDA and Europol; 
and (iii) in line with the lessons learned from the impact of the COVID-19 
pandemic on drug markets. All stakeholders should strive to align EMPACT 
on the one hand, and the EU Drugs Strategy and Action Plan on the other 
hand, in the best possible way in terms of both process and content. 
Increase coordination and cooperation at both law enforcement and 
judicial level to achieve more tangible investigative results, including 
through EMPACT, as well as increased exchange of information on drug- 
related organised crime groups, domestic and international, and increased 
use of the Secure Information Exchange Network Application (SIENA).
1.1. Target high-risk organised crime 
groups active across the EU and cross- 
border drug markets; set priorities in 
synergy with the EU policy cycle for 
organised and serious international 
crime (EMPACT); disrupt criminal 
business models, especially those that 
foster collaboration between different 
organised crime groups; and address 
links with other security threats.
2021-2025 Member States








Reinforce information sharing and analysis between law enforcement and 
other relevant agencies:
2.1 regarding illicit drug production, trafficking and distribution. This 
should include i.a. immediate information exchange between Member 
States in cases of seizures of large quantities of drugs, identification of 
high-risk criminals, criminal networks and structures, as well as 
international references.
2.2 related to other forms of serious crime which are linked to drug crime, 
such as violence, homicide, corruption, money-laundering, trafficking in 
human beings, migrant smuggling, trafficking of firearms and terrorism.
1.1
1.2 Track, trace, freeze and confiscate 
the proceeds of and instruments used 
by organised crime groups involved in 
the illicit drug markets.
2021-2025 Member States








Enhance investigations on drug related organised crime groups and 
networks posing the highest security risk in the EU through a high-value 
target selection process established by the Member States with the support 
of Europol. An integral part of such investigations should be asset-tracing 
and financial investigations to lead to the effective confiscation of proceeds 
of drug crime. Ensure increased cooperation and coordination of 
operational activities (such as controlled deliveries of drugs and joint 
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Action Priority area Timetable Responsible party (1)
third countries and Europol; also increase cooperation with Eurojust on 
related judicial prosecution.
Action 4
Ensure that Member States give competent authorities swift access to 
financial information to allow them to carry out effective financial 
investigations of drug-related organised crime groups, including by: (i) 
making full use of information held by Financial Intelligence Units (FIUs) 
under the conditions laid down by the Directive on the use of financial 
information (Directive (EU) 2019/1153); (ii) making more effective use of 
information gathered by Asset Recovery Offices to identify and track profits 
linked to drug trafficking, with a view to their possible subsequent freezing 
and confiscation; (iii) strengthening their cooperation with prosecutors and 
judges ultimately responsible for applying for and issuing the necessary 
freezing and confiscation orders and warrants for search and seizure. 
Increase training for law enforcement and judicial investigators and the 
local and regional specialised units dedicated to the seizures of criminal 
assets.
1.2 2021-2025 Member States






Increase active and reciprocal cooperation and establish better links 
between tax/customs authorities and law enforcement in order to (i) 
enhance investigations, (ii) detect trade-based money-laundering activities; 
(iii) disrupt criminal activities and (iv) stop profits from drug markets going 
back into furthering criminal activities or into the legal economy. Member 
States are encouraged to build their expertise and resources on alternative 
banking and money transfer systems used by drug-related organised crime 
groups (e.g. Hawala).
1.2 2021-2025 Member States




Identify and prioritise cooperation with high-risk countries from a drug 
production and smuggling perspective in an effort to facilitate Member 
States’ access to financial and other information in order to strengthen the 
capacity of the competent authorities to investigate and prosecute drug- 
related crime and conduct financial investigations, and subsequently, to 
track and trace drugs-related criminal proceeds and ensure that EU-based 
seizure and confiscation orders are executed.
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Action Priority area Timetable Responsible party (1)
Action 7
Improve possibilities to tackle encryption in line with the resolution on 
security through encryption and security despite encryption adopted by the 
Council in December 2020, and other new technology-related methods 
employed by organised crime groups active in the drug markets to avoid 
detection and hide their communications. In this context, Europol 
analytical and technical capacities to support the Member States in this area 
should be strengthened and mutual legal assistance should be facilitated 
and strengthened, in particular regarding standard measures (e.g. subscriber 









Following the effective confiscation of assets, take into consideration the 
safe and secure reuse of seized and confiscated instrumentalities in support 
of drug demand and supply reduction measures, in accordance with 
national legislation. The European Commission will further consider the 
effective confiscation of assets within the scope of the possible revision of 
the Directive on the freezing and confiscation of instrumentalities and 




Council of the EU
Member States
Action 9
(i) Promote and support the work and best practices of the European Crime 
Prevention Network (EUCPN) and other relevant projects with a view to 
reducing recidivism among young drug-related crime offenders; (ii) 
encourage comprehensive evidence-based strategies in neighbourhoods 
that experience high levels of drug availability and drug-related crime and 
(iii) support measures that create a more protective environment for 
communities affected by the consumption and sale of drugs or drug-related 
crime, in accordance with internationally recognised quality standards (2).
1.3 Prevent drug related crime with 
particular focus on the need to counter 
violence, limit corruption and address 
the exploitation of vulnerable groups 
by addressing the underlying factors 




Council of the EU
European Commission
EMCDDA
(1) The stakeholders listed as responsible parties are the stakeholders involved in the implementation of the action concerned. The involvement of responsible parties for the implementation of the Action Plan 
shall be in accordance with their respective role as defined in applicable Union legislation and in their mandate.
(2) UNODC/WHO International Standards on Drug Use Prevention
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Strategic priority 2: Increase the detection of illicit wholesale trafficking of drugs and drug precursors at EU points of entry and exit
Action Priority area Timetable Responsible party
Action 10
Support activities at drug trafficking entry and exit points by reinforcing and 
promoting the establishment of police and customs risk analysis, 
investigation methods, and other relevant policies, controls and procedures 
to counter drug trafficking. Ensure structured coordination and cooperation 
as well as exchange in real time of crime intelligence and coordinated 
investigations in the EU by using the services of relevant EU agencies such as 
Europol and Frontex to support Member States. Member States should also 
ensure that real-time information exchange among competent authorities at 
the entry/exit points is directly connected to SIENA.
2.1 Counter the smuggling of drugs 
and drug precursors in and out of the 
EU by using established legitimate 
trade channels.
2021-2025 Member States





Support Member States in the development of effective screening 
technologies capable of detecting drugs and drug precursors for containers, 
trucks and ships, focusing on major ports, airports, train stations and major 
land border crossings.
2.1 2021-2025 Member States





Improve structured coordination and cooperation between customs and 
Frontex, Europol and EMCDDA within their respective mandates, as well as 
exchange of customs information, to be interoperable and combined with 
that of law enforcement and border control, where appropriate. Increase 
the customs expertise within Europol, and reinforce the capability of 
Frontex border guards to detect drug trafficking at the EU’s borders.
2.1 2021-2025 Member States






Establish the necessary links and cooperation with the relevant civil aviation 
and maritime authorities, where appropriate through formal agreements, in 
order to ensure effective and efficient investigations and detection of drugs at 
airports and ports, taking into account relevant international regulation and 
instruments issued by the International Labour Organization, International 
Maritime Organization and International Civil Aviation Organization. 
Strengthen international cooperation with maritime and civil aviation 
authorities in key partner countries along major drug trafficking routes, 
where appropriate through formal agreements.
2.1
2.2 Increase monitoring of border 
crossings that are not part of 
established trade channels to more 
effectively prevent illicit or undeclared 
crossings of the EU external borders.
2021-2025 Member States






Continue financing and providing the Maritime Analysis and Operation 
Centre - Narcotics (MAOC-N) with a sustainable long-term governance 
model. Ensure exchange of information and cooperation with the relevant 
EU agencies.
2.2. 2021-2025 European Commission
MAOC-N
Member States
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Further develop the drug intelligence fusion platform at Europol, including 
links with relevant EU agencies and MAOC-N, and enhance information 
exchange and investigative actions with third countries and regions 
constituting major source or transit hubs for drugs affecting Member States, 
in accordance with applicable legislation. Use the services of Europol to 
support and promote related activities and to facilitate information 
exchange with Member States’ bilateral liaison officers already placed at the 
geographical drugs hubs.





Council of the EU
EEAS
Action 16
Conclude agreements between the European Union and third countries 
where drug trafficking hubs are located, enabling relevant EU agencies such 
as Europol and Frontex to exchange information and data, including 
personal and operational data, where appropriate.
2.2 2021-2025 European Commission
Europol
Frontex
Council of the EU
EEAS
Strategic priority 3: Tackle the exploitation of logistical and digital channels for medium- and small-volume illicit drug distribution and increase seizures of illicit substances smuggled through these 
channels in close cooperation with the private sector
Action Priority area Timetable Responsible party
Action 17
Monitor internet and darknet marketplaces for drugs by implementing the 
preparatory action proposed by the European Parliament on 24/7 
monitoring of the darknet to ensure comprehensive results (1). Reinforce 
EMCDDA’s and Europol’s capacities in this area.






Council of the EU
Action 18
Operational feasibility analysis of how postal and express services can 
detect and prevent distribution of illicit substances in postal items (2). 
Conclude Memoranda of Understanding with the objective of enhancing 
cooperation between law enforcement, customs, postal and express 
services and electronic payment providers.
3.2. Target drugs trafficking via 
postal and express services.
2021-2025 European Commission
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Action Priority area Timetable Responsible party
Action 19
Promote the development, use and exchange of best practices and 
equipment among Member States on monitoring of suspicious postal items 
by employing solutions such as detection dogs and/or x-ray machines. 
Notably, the role of new technologies and especially of artificial intelligence 
should be examined, while preserving the fundamental right of privacy of 
correspondence.
3.2 2021-2025 Member States
European Commission
Council of the EU
Action 20
Raise awareness of the need to focus actions on drug trafficking channels 
currently insufficiently monitored by law enforcement, by establishing or 
reinforcing monitoring and investigation methods for smaller sea harbours 
and fluvial ports, airfields, and train and bus stations. Involve relevant EU 
agencies to support Member States in these activities within their respective 
mandates.
3.3. Reinforce monitoring and 
investigation methods for cross-EU 
rail and fluvial channels and the 
general aviation space.
2021-2025 Member States




(1) For details, see Item 18 02 77 04 — Preparatory action — EU-coordinated Darknet monitoring to counter criminal activities, on page 61 of Annex 3, PP/PA budgetary remarks.
(2) Postal item: an item addressed in the final form in which it is to be carried by a postal service provider. In addition to items of correspondence, such items also include, for instance, books, catalogues, 
newspapers, periodicals and postal parcels containing merchandise with or without commercial value.
Strategic priority 4: Dismantle illicit drug production and counter illicit cultivation; prevent the diversion and trafficking of drug precursors for illicit drug production; and address environmental damage
Action Priority area Timetable Responsible party
Action 21
Identify, track and dismantle illicit drug producing facilities in the EU, 
including by targeting precursors and designer precursors, by improving 
and making better use of forensic investigations and intelligence and by 
developing and expanding detection techniques, making better use of 
public-private partnerships and enhancing the reporting of suspicious 
transactions.
4.1. Counter illicit production of 







Consider launching a study assessing the effectiveness of Council 
Framework Decision 2004/757/JHA of 25 October 2004 laying down 
minimum provisions on the constituent elements of criminal acts and 
penalties in the field of illicit drug trafficking, with a view to amending 
possibly outdated aspects and strengthening areas as needed, including the 
provisions on NPS.
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Action Priority area Timetable Responsible party
Action 23
Address the main challenges identified by the evaluation of the drug 
precursors regulations, in particular the need to address the challenge posed 
by designer precursors.
4.2. Tackle the diversion and 
trafficking of drug precursors and the 
development of alternative chemicals.
2021-2022 European Commission
Member States
Council of the EU
Action 24
Boost the operational activities of law enforcement agencies and their 
cooperation with administrative authorities and other relevant parties with 
regard to the fight against environmental crime related to illicit drug 
production and trafficking, the transfer, custody and storage of drugs, 
precursors and seized equipment, and the destruction and treatment of the 
waste produced, as well as their associated costs where possible.
Develop detection technologies, information exchange and coordinated 
investigations by involving relevant EU agencies to support Member States, 
including to develop a comprehensive method regarding the 
implementation and coordination of efficient and environment-friendly 
disposal of waste.
4.3. Address environmental crime 
related to illicit drug production and 
trafficking.
2021-2025 Member States





II - DRUG DEMAND REDUCTION: PREVENTION, TREATMENT AND CARE SERVICES
Strategic priority 5: Prevent drug use and raise awareness of the adverse effects of drugs
Action Priority area Timetable Responsible party
Action 25
Implement and, where needed, increase the availability of evidence-based 
environmental and universal prevention interventions and strategies, based 
on life skills. These should address the links between addictions to illegal, as 
well as legal, substances and behavioural addictions.
5.1. Provide, implement and, where 
needed, increase the availability of 
evidence-based environmental and 
universal prevention interventions 
and strategies for target groups and 
environments, in order to increase 
resilience and strengthen life skills and 
healthy life choices.
2021-2025 Member States




Expand and promote cross-EU educational campaigns, taking into 
consideration local and regional needs, targeted at families, teachers, social 
workers and local decision makers, to increase their knowledge and support 
them in increasing health literacy and promoting positive behaviour, a 
5.1 2022-2025 European Commission
EMCDDA Member States
Council of the EU
EN
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Action Priority area Timetable Responsible party
healthy lifestyle, and a safe environment for young people and other 
groups, with the objective of preventing them from taking illicit drugs and 
engaging in risk behaviours and in drug market-related crime/activities.
Action 27
Increase the availability of reliable information on prevention, including 
effective models of prevention, as available on the EMCDDA Best Practice 
Portal and encourage the wider adoption of prevention programmes that 
have proven to be effective, including innovative activities with 
demonstrable effectiveness.
5.1 2022-2025 Member States




Promote the inclusion of preventive messages with demonstrable 
effectiveness in communication and social media channels addressed to 
young people and other vulnerable groups. Roll out targeted rapid alert risk 
communications and intelligence notifications when dangerous 
substances, including new psychoactive substances (NPS), or other 
emerging threats appear on the market including, where appropriate and in 
accordance with national legislation, using information from drug 
checking.
5.2. Provide, implement and, where 
needed, increase the availability of 
evidence-based targeted prevention 





Council of the EU
Action 29
Provide for and increase the partnership approach in the provision of 
effective evidence-based selective and indicated prevention measures to 
prevent the development of risk behaviours and reduce progression into 
severe drug use disorders, among those experiencing multiple 
disadvantages, such as homelessness, dual diagnosis, migrants, refugees and 
victims of violence, including gender-based violence. Also for young people 
in multiple settings, including schools, families and community, in 
recreational and workplace settings, as well as people in high-risk 
environments Collaboration efforts should be enabled between all 
stakeholders, including parents and families, those working in education or 
family support networks, youth services, student unions, sporting 
organisations and networks of people who use drugs.
Implementation of these measures may rely on trained professionals, in 
particular from primary healthcare, to better identify substance use issues 
and include the use of brief and early interventions, and utilise novel digital 
health communication and the social media channels.
5.3. Provide, implement and, where 
needed, increase the availability of 
evidence-based early intervention 
measures.
2021-2025 Member States
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Action Priority area Timetable Responsible party
Action 30
Promote and allocate sufficient funding for education, training and 
continuous professional development for decision makers, opinion leaders 
and professionals on the latest scientific evidence on drug use and addiction 
prevention, including new consumption patterns, also using online tools, 
and in particular promote the implementation of the European Drug 
Prevention Quality Standards (EDPQS), the UNODC/WHO International 
Standards on Drug Use Prevention and the European Prevention 
Curriculum (EUPC) training courses.
5.4. Disseminate the latest scientific 
evidence on prevention to decision 
makers and practitioners and provide 
them with training.
2022-2025 Member States




Implement activities that raise awareness of the risks of driving while 
impaired by drugs and disseminate best practices of testing and early 
intervention models targeted especially to young drivers. Support research 
and innovation of on-site drug detection tools and explore the possibility of 
including considerations on drugs in the EU Recommendation on 
permitted blood alcohol content for drivers.
5.5. Address drug-impaired driving. 2021-2025 Member States
Council of the EU
European Commission
EMCDDA
Strategic priority 6: Ensure access to and strengthen treatment and care services
Action Priority area Timetable Responsible party
Action 32
Develop and ensure voluntary, non-discriminatory and gender-sensitive 
access to effective evidence-based drug treatment, including person-centred 
opioid maintenance therapy, risk and harm reduction, rehabilitation 
services, social reintegration and recovery support including 
comprehensive services for people with co-morbidity. Ensure that these 
services are well-coordinated at service level on the case management 
principle to provide the full continuum of care and be both as effective as 
possible and focused on life stages, with a particular focus on homeless and 
vulnerable people. These measures, based on the WHO/UNODC 
International Standards for the Treatment of Drug Use Disorders, should 
also address poly drug use, ageing drug users, needs of families of people 
who use drugs and patients with coexistent drug addiction and other 
physiological or behavioural addictions.
6.1. Ensure voluntary access to 
treatment and care services that work 
in close coordination and 
collaboration with other health and 
social support services.
2021-2025 Member States
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Action Priority area Timetable Responsible party
Action 33
Develop and implement training for staff working in treatment and care 
services and those dealing with drug issues in generic health or social 
support services, on the basis of evidence-based measures, identifying 
curricula that cover both core and advanced competencies and encouraging 
the sharing of best practices and partnerships between training providers.
6.1 2021-2025 Member States




Support innovation in treatment delivery and improve and promote the use 
of electronic and mobile health delivery options and new 
pharmacotherapies in order to ensure access to drug treatment for all target 
groups. Assess the effectiveness of such approaches with the possibility of 
scaling up those interventions that have proven to be most effective.
6.1 2021-2025 Member States




Recognise and promote peer-led outreach and peer group work. Support 
the opportunities for peer workers to be added to the multidisciplinary 
treatment workforce. Invite expert peers to working groups and hearings.
6.2. Promote peer work. 2021-2025 Member States




Identify, address and reduce barriers to accessing drug treatment, risk and 
harm reduction, social rehabilitation and recovery, especially with regard to 
demographic and personal barriers and ensure that healthcare and social 
services are funded and appropriate to the needs and the key characteristics 
of their client groups, and take into account new realities i.e. the COVID-19 
pandemic.
6.3. Identify and remedy the barriers 
to accessing treatment and ensure and, 
where needed, extend coverage of 
treatment and care services based on 
individual needs.
2021-2025 Member States




Extend the evidence base on cannabis-related problems, including those 
related to synthetic cannabinoids, and improve understanding of both 
treatment needs and what constitutes effective interventions when 
responding to these substances.
6.3 Member States




Continue and further develop the implementation of the EU minimum 
quality standards adopted by the Council in 2015 (1) and evidence-based 
guidelines in national guidelines and programmes.
6.3 2021-2025 Member States
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Action Priority area Timetable Responsible party
Action 39
Develop and provide training for decision makers, employers and 
professionals about stigma linked to drug use and drug-use disorders, and 
mental health, and consider the impact that this stigma may have had on 
patients when delivering care. This should be done with the involvement of 
people who have experienced drug-related stigma.
6.4. Reduce stigma. 2021-2025 Member States




Identify and reduce barriers to treatment and other services utilisation for 
women who use drugs, and ensure that drug-related services respond to the 
needs of women e.g. including childcare support. Launch outreach efforts 
to reach women who use drugs and raise awareness of available women- 
centred treatment and also tackle gender-based violence towards women 
who use drugs. Ensure that women who are victims of violence and use 
drugs have access both to drug prevention and to support and treatment in 
order to break the cycle of drug use and the vulnerability to violence.
6.5. Widely implement treatment 
and care addressing the specific needs 
of women.
2021-2025 Member States




Provide services that can address the diversity existing among groups with 
special care needs in relation to problem drug use, including comorbidity, 
also engaging with models of care that recognise the need for cross-service 
partnerships between healthcare, youth and social care providers, and  
patients/carers groups.
6.6. Implement models of care that 
are appropriate for groups with 
special care needs.
2021-2025 Member States




Promote and implement capacity-building and awareness-raising activities 
regarding access to and availability of controlled substances for medical and 
scientific purposes, bearing in mind the risk of misuse and diversion and in 
this regard, provide an overview of the up-to-date evidence on the use of 
controlled substances for medical and scientific purposes.
6.7. Provide and, where needed, 
improve access to, availability and 
appropriate use of substances for 
medical and scientific purposes.
2021-2025 Member States




(1) Council Conclusions on the implementation of the EU Action Plan on Drugs 2013-2016 regarding minimum quality standards in drug demand reduction in the European Union 11985/15.
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III - ADDRESSING DRUG-RELATED HARM
Strategic priority 7: Risk- and harm-reduction interventions and other measures to protect and support people who use drugs
Action Priority area Timetable Responsible party
Action 43
Maintain and where needed enhance access to effective risk and harm 
reduction measures, also guided by the EU minimum quality standards in 
drug demand reduction, such as needle and syringe programmes, opioid 
agonist treatment, peer-based interventions and outreach programmes, in 
accordance with national legislation. These measures need also to improve 
the social situation of people who use drugs, housing, their financial 
situation, employment and education, including programmes utilising peer 
support and self-help initiatives.
Further extend the exchange of best practices in this area among Member 
States, and with partners such as third countries, regions and international 
organisations, and implement and promote professional training on these 
measures.
7.1. Reduce the prevalence and 
incidence of drug-related infectious 
diseases and other negative health and 
social outcomes.
2021-2025 Member States




Maintain and, where needed, scale up measures to reduce the prevalence of 
drug-related infectious diseases, in particular the early diagnosis of 
Hepatitis C and HIV/AIDS, promoting rapid testing and self-testing for HIV 
and outreach programmes to reach the most vulnerable people. Where 
needed, enhance access to treatment after diagnosis to eradicate hepatitis C 
and achieve the UNAIDS 90-90-90 target for 2030. Promote the diagnosis 
of tuberculosis among people who use drugs and homeless people.
7.1 2021-2025 Member States




Improve and increase the ability to identify, assess and respond, at national 
and EU levels and via the EU Early Warning System on NPS, to new trends 
and developments in drug use, including changes due to epidemic 
outbreaks.
7.1 2021-2025 Member States





Continue to reduce drug-related deaths and non-fatal overdoses (including 
the role played by poly substance use), by introducing, maintaining and 
where needed enhancing measures to reduce fatal and non-fatal overdoses, 
and other risk and harm reduction and policy measures, where appropriate 
and in accordance with national legislation, including: (i) opioid agonist 
treatment, including take-home naloxone programmes; (ii) supervised drug 
consumption facilities; (iii) innovative approaches including digital health 
for people who use stimulant drugs and for young people in nightlife 
settings, such as peer-led outreach work, online street work in user fora or 
drug checking. Support training, the evaluation of effective approaches and 
the exchange of best practices in this area and further improve the 
7.2. Prevent overdoses and drug- 
related deaths.
2021-2025 Member States
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Action Priority area Timetable Responsible party
monitoring and real-time reporting of non-fatal intoxications and overdose 
deaths across the EU, with a view to developing an overall target for the 
reduction of drug-related deaths in the EU.
Action 47
Strengthen efforts to share forensic and toxicological data: (i) enhance 
analytical methods, test and promote new techniques; (ii) exchange best 
practices and develop joint training; (iii) increase cooperation with the 
Commission’s Joint Research Centre and the EMCDDA, and through 
existing networks, such as the REITOX network of Focal Points, the Drugs 
Working Group of the European Network of Forensic Science Institutes and 
the Customs Laboratories European Network. Develop and recommend for 
implementation a set of European forensic toxicology guidelines for drug- 
related death investigations.
7.2 2021-2025 Member States




Promote and encourage the active and meaningful participation and 
involvement of civil society, including non-governmental organisations, 
young people, people who use drugs, clients of drug-related services, the 
scientific community and other experts in the development, implementation 
and evaluation of drug policies and provide an appropriate level of resources 
for all drug services and for the involvement of civil society.
7.3. Promote civil society 
participation and ensure sustainable 
funding.
2021-2025 Member States




Scale up the availability, effective implementation, monitoring and 
evaluation of measures provided as alternatives to coercive sanctions (1) for 
drug-using offenders and for people in pre-trial detention, arrested, charged 
with or convicted of drug-related offences or people found in possession of 
drugs for personal use, such as (suspension of sentence with) treatment, 
rehabilitation and recovery, and social reintegration, in accordance with 
national legislation. Follow-up to the Study on alternatives to coercive 
sanctions as response to drug law offences and drug related crimes 
concluded in 2016, e.g. through a possible Commission Recommendation 
on the topic that respects the different national approaches on the matter 
and the Member States’ competence to legislate in this field. Produce more 
comprehensive and in-depth data, including on implementation barriers, 
and share and exchange best practices on alternatives to coercive sanctions, 
including research on responses to drugs-related offences of drug 
consumption and/or drug possession for personal use, taking into account 
differences in the national legislation of the Member States.
7.4. Provide alternatives to coercive 
sanctions.
2021-2025 Member States
Council of the EU
European Commission
EMCDDA
(1) The term ‘alternatives to coercive sanctions’ could, according to the national legislation of the Member States, also refer to alternatives that are used instead of or alongside the traditional criminal justice 
measures for drug-using offenders (see Council conclusions: Promoting the use of alternatives to coercive sanctions for drug using offenders, 8 March 2018).
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Strategic priority 8: Address the health and social needs of people who use drugs in prison settings and after release
Action Priority area Timetable Responsible party
Action 50
Ensure evidence-based drug services, including opioid agonist treatment, 
rehabilitation and recovery, developing a continuum of care model in 
prison settings and the probationary service for drug using offenders, 
together with provisions to reduce stigma. It is essential to provide 
continued access to evidence-based drug services, equivalent to that 
provided in the community.
8.1. Assure equivalence and 
continuity of healthcare provision in 
prison and by probationary services.
2021-2025 Member States




Facilitate the development of a balanced and comprehensive policy 
response to drug issues in prisons and provide guidelines for Member States 
for this purpose.
8.1 2024 European Commission
EMCDDA
Member States
Council of the EU
Action 52
Scale up access to testing and treatment for blood-borne infections 
alongside other evidence-based preventive measures that reduce the health 
risks associated with drug use in prison settings in the same way as is done 
in the community, implemented by well-trained staff or peers.
8.2. Implement evidence-based 
measures in prison settings to prevent 
and reduce drug use and its health 
consequences, including measures to 
address the risk of drug-related deaths 
and the transmission of blood-borne 
viruses.
2021-2025 Member States




Reduce overdoses and drug-related mortality in prison and upon release, by 
providing overdose awareness training and where possible take-home 
naloxone. Upon release, provide drug-using offenders with access to 
healthcare and social services, employment, housing and support for 
reintegration into society.
8.3. Provide overdose prevention and 
referral services to ensure continuity 
of care on release.
2021-2025 Member States




Implement training for prison staff to better detect drugs entering prisons, 
increase awareness of the issue and implement evidence-based health 
related drug responses within the prison environment. Increase 
cooperation with law enforcement and other relevant agencies.
8.4. Restrict the availability of drugs 
in prisons.
2021-2025 Member States
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IV - INTERNATIONAL COOPERATION
Strategic priority 9: Strengthening international cooperation with third countries, regions, international and regional organisations, and at multilateral level to pursue the approach and objectives of the 
Strategy, including in the field of development. Enhancing the role of the EU as a global broker for a people-centred and human rights-oriented drug policy
Action Priority area Timetable Responsible party
Action 55
Contribute to shaping the international agenda on drugs policy in line with 
the approach and objectives of the EU Drugs Strategy 2021-2025, 
including by accelerating the implementation of joint multilateral 
commitments such as the 2030 Agenda for Sustainable Development and 
the outcome document of the 2016 United Nations General Assembly 
Special Session on the world drug problem (UNGASS) and in the context of 
the mid-term review of the 2019 Ministerial Declaration of the 
Commission on Narcotic Drugs in 2024.
9.1. Continue shaping the 
international and multilateral agendas 
on drug policy.
2021-2025 Member States




Strengthen partnerships with UNODC, WHO, INCB and other relevant UN 
bodies, including in support of the UN System Common Position, and 
relevant international and regional bodies, organisations and initiatives, 
focusing on drug policies, health, human rights and development and in 
support of global evidence-based research and data collection.
9.1 2021-2025 Member States




Continue and reinforce, as appropriate, established drugs dialogues or 
meetings with partners in the Western Balkans, the Eastern Partnership, 
Central Asia and Latin America and the Caribbean, as well as with Russia, 
the USA, China and Iran.
9.2. Ensure a sustainable level of 
dialogue and information sharing on 
the strategies, aims and relevant 
initiatives with third countries or 
regions.
2021-2025 Member States






Dublin Group to use its potential and the potential of its regional reports to 
analyse and exchange views on the drugs situation in various regions of the 
world, and on ways to address this situation.
9.2 2021-2025 Member States






HDG to hold discussions with a view to assessing the relevance of 
launching new dedicated drugs dialogues or meetings with other priority 
countries and/or regions, taking into account their strategic relevance from 
the drugs perspective and EU relations, and approving the objectives, scope 
and modalities of such dialogues or meetings.
9.2 2021-2025 Member States
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Action Priority area Timetable Responsible party
Action 60
Strengthen, where relevant, the role of the EU agencies, especially the 
EMCDDA and Europol, but also Eurojust, in international cooperation in 
the field of drugs, in a way that ensures synergies with the role of other 
international actors, and, where relevant, in a way that promotes 
complementarity with international tools and standards, and ensure regular 
and timely reporting of relevant and operational information between 
cooperation programmes and these EU agencies.
9.3 Foster international cooperation 
by further involving competent EU 







Council of the EU
EEAS
Action 61
Strengthen existing cooperation initiatives and programmes where possible 
and relevant, based on regular evaluations and if applicable launch new 
ones to support third countries and other partners’ efforts to address drug- 
related challenges, including as regards public health, development, safety 
and security issues, as well as human rights.
9.4. Continue, and establish new 
cooperation programmes with third 
countries or regions and other 





Council of the EU
Action 62
Provide targeted technical assistance and support, as necessary, to candidate 
countries and potential candidates to facilitate their alignment with the EU 
acquis in the drugs field.




Council of the EU
EEAS
Action 63
Foster synergies, including by ensuring exchange of information within the 
HDG, on drug-related cooperation programmes with third countries 
funded by the EU and/or by the Member States.
9.4 2021-2025 European Commission
Member States
Council of the EU
EEAS
Action 64
Strengthen the EU’s international coordination and cooperation in the 
fields of drug-related crime prevention, law enforcement and judicial 
cooperation, including the possible links with terrorism, organised crime 
and other forms of transnational crime, as defined in the UN legal 
framework and in full compliance with international human rights 
obligations. International cooperation should also be enhanced to ensure 
the fight against money laundering and in the field of seizure and 
confiscation of assets.
9.5. Address all the policy aspects of 
the Strategy in international 
cooperation, including in the fields of 
security and judicial cooperation as 







Council of the EU
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O
fficial Journal of the European U
nion 
8.7.2021                                                                                                                                          
C 272/19  
Action Priority area Timetable Responsible party
Action 65
Enhance international cooperation to address the health- related aspects of 
drug use, especially in the fields of prevention, treatment, risk and harm 
reduction, social reintegration, and alternatives to coercive sanctions in line 
with human rights obligations. International cooperation should also be 
enhanced to promote increased access to and availability of controlled 
substances for medical and scientific purposes.
9.5 2021-2025 European Commission
EEAS
Member States
Council of the EU
Action 66
Further promote an integrated approach to Alternative Development in 
line with the Council Conclusions on Alternative Development (1)(2018), in 
cooperation with third countries (2).
9.6. Strengthen the commitment to 
development-oriented drug policies 





Council of the EU
Action 67
Strengthen the commitment and provide an appropriate level of EU and 
Member State’s funding and expertise to alternative development 
programmes and related development-centred drug policy interventions 
within the framework of the 2030 Agenda for Sustainable Development 
and according to the OECD Development Assistance Committee’s (DAC) 
criteria beyond an exclusive focus on illicit drug crop monitoring indicators 
and ensuring ownership among target communities.
9.6 2021-2025 European Commission
EEAS
Member States
Council of the EU
Action 68
Ensure that the monitoring, protection and promotion of human rights are 
fully integrated in the EU’s relations with, and external assistance to, third 
countries, regions and international organisations, and take into account, 
among others, different parts of the International Guidelines on Human 
Rights and Drug Policy as relevant.
9.7. Protect and promote adherence 
to international human right 





Council of the EU
Action 69
Reaffirm the EU’s strong and unequivocal opposition to the death penalty 
in all circumstances, including for drug-related offences, and promote the 





Council of the EU
(1) Council Conclusions on Alternative Development: ‘Towards a new Understanding of Alternative Development and Related Development- centered Drug Policy Interventions – Contributing to the 
Implementation of UNGASS 2016 and the UN Sustainable Development Goals’.
(2) taking into account specific framework conditions, including: assuring full compliance with international human rights obligations and adhering to the principles of gender equality, non-conditionality, non- 
discrimination and proper sequencing when designing, implementing and evaluating alternative development programmes, as well as stressing the environmental and climate considerations linked to illicit 
drug crop cultivation and drug production.
EN
O
fficial Journal of the European U
nion 
C 272/20                                                                                                                                           
8.7.2021  
V - RESEARCH, INNOVATION AND FORESIGHT
Strategic priority 10: Building synergies to provide the EU and its Member States with the comprehensive research evidence base and foresight capacities necessary to enable a more effective, innovative and 
agile approach to the growing complexity of the drugs phenomenon, and to increase the preparedness of the EU and its Member States to respond to future challenges and crises
Action Priority area Timetable Responsible party
Action 70
Strengthen and broaden research, information, monitoring, evaluation and 
modelling capacities of the EU and its Member States, including by making 
use of new technologies, by i) identifying and prioritising knowledge gaps 
and testing capacities; ii) supporting coordination, networking and other 
activities necessary to create synergies across the European research 
community and iii) ensuring the efficient and accurate collation and 
presentation of European data needed for international reporting and 
assessment purposes, mindful of profiting of synergies and avoiding 
duplications. All data based on individuals should be disaggregated by sex 
and the collection and presentation of data should consider the gender- 
sensitive aspects of drug policy.
10.1. Strengthen and broaden 
research capacities and encourage the 





Council of the EU
Action 71
Improve preparedness to possible future challenges and opportunities by: i) 
identifying the lessons learnt from the COVID-19 pandemic and its impact 
on service delivery, drug markets, patterns of use and harm; ii) investing in 
the development of new methods and technologies and analytical 
techniques (such as developments in forensic and toxicologcal methods; 
information technologies, detection tools, statistical modeling; 
telemedicine and use of big data and open source information) needed to 
better identify emerging threats and innovative responses and iii) creating 
synergies and supporting the sharing of best practice in the innovations and 
future domains in the work of EMCDDA and Europol.
10.2. Foster innovation, so that 
policy and actions shift from a 





Council of the EU
Action 72
Improve EU resilience by increasing the capacity to predict and respond to 
potential threats, trends and developments by: i) conducting a strategic 
review during the course of the action plan to identify any important new 
emerging threats and to allow mitigating measures to be developed; ii) 
encouraging regular horizon-scanning activities and networking relating to 
demand and supply, where links with drug problems and opportunities 
exist or may emerge in the future, including policy developments with 
respect to internationally controlled narcotic drugs and psychotropic 
substances, including information on cannabis developments.






Council of the EU
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Action Priority area Timetable Responsible party
Action 73
Increase the value and complementarity of European research efforts by: i) 
continuing to provide adequate support for existing information collection 
mechanisms; ii) recognising and developing, where possible and 
appropriate, the role played by EMCDDA and Europol in the European 
research knowledge cycle; iii) regular reviewing of research needs, 
coordination mechanisms and how synergies can be enhanced at the 
European level and iv) strengthening the role of the EMCDDA and Europol 
to ensure that the agencies, and the Reitox network of national focal points, 
have the means, including financial resources, to support the EU and its 
Member States with the robust high-quality evidence base necessary to 
respond effectively to the drug-related policy challenges, including the 
strengthening of early warning approaches.
10.4. Strengthen coordination and 
synergies, and support the central role 
of the EMCDDA, Europol and the 
Reitox network of national focal 






Council of the EU
Action 74
Promote, where possible, appropriate financing of EU-level drug-related 
research, innovation and foresight, including through EU cross-sectoral 
funding sources and appropriately support the efficient targeting, 
coordination and sustainability of drug-related research efforts.
10.5. Ensure adequate financing for 




Council of the EU
VI - COORDINATION, GOVERNANCE AND IMPLEMENTATION
Strategic priority 11: Ensuring optimal implementation of the Strategy and of the Action Plan, coordination by default of all stakeholders and the provision of adequate resources at EU and national levels
Action Timetable Responsible party
Action 75
Member States to compile and provide, when required, the available national data needed for monitoring 
the implementation of the Strategy and its Action Plan, as well as the impact of implementation, where 
possible. All actors involved as responsible parties shall, within the context of their mandate, collect and 
analyse the available data or seek where possible to develop or improve existing data sources where they 
are inadequate, so as to provide the information necessary for the implementation of the action in 
question. The European Commission, taking into account the information provided by the Member 
States and with the support of the EEAS, EMCDDA, Europol, other EU bodies and civil society, shall 
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Action Timetable Responsible party
Action 76
The Presidency of the Council to organise within the HDG dedicated discussions or exchanges of best 
practices which could provide support to the Member States in the implementation of the Strategy and 
of the Action Plan, with expert input where appropriate.
2021-2025 Member States






The Commission, on the basis of the information provided by the Member States, the EEAS, the 
EMCDDA, Europol, other relevant EU institutions and bodies and civil society, to initiate an overall 
external evaluation of the implementation of the Strategy and of the Action Plan and transmit the results 
of this evaluation to the European Parliament and to the Council, as soon as they are available, and at the 
latest by 31 March 2025. On the basis of these results, to organise within the HDG discussions that will 
form the basis for the definition of the future development of EU drug policy and the following cycle of 





Council of the EU
EEAS
Action 78
Member States to conduct evidence-based evaluations of policies and interventions on a regular or 
ongoing basis and share with EU partners findings and methodologies.
2021-2024 Member States





Allocate, from cross-sectoral funding sources, appropriate and targeted resources (provided by the EU 




Council of the EU
EEAS
Action 80
Review the mandate of the EMCDDA following the evaluation completed in 2019 (1) to ensure that the 
agency plays a stronger part in addressing the current and future challenges of the drug phenomenon. 





Council of the EU
Action 81
Facilitate synergies and complementarity between the drug-related policies of the EU and the Member 
States, and between the drug-related activities of EU Institutions and other bodies as well as coordination 




Council of the EU
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Action Timetable Responsible party
Action 82
The Presidency of the Council to keep HDG, as the main coordinating body on drug policy, informed on 
drug-related activities in other preparatory bodies of the Council, such as the Standing Committee on 
Operational Cooperation on Internal Security (COSI) and the Working Party on Public Health, as well as 
other relevant Council preparatory bodies, including in the area of customs, judicial and criminal 
matters, law enforcement, social affairs, agriculture and external relations, with the support of the EEAS 
for those that they are chairing. The Commission, the EEAS and the Member States to proactively update 
all partners in the HDG on drug-related developments in which they are involved.
2021-2025 Member States




Member States to work towards efficient systems of collaboration between drug policy and the other 
relevant policies, including in the law enforcement/security and health/social policy fields, involving the 
relevant stakeholders in the various areas.
2021-2025 Member States
Council of the EU
European Commission
Action 84
The EU and its Member States to promote the EU approach to drug policy, in particular when acting in 
the international scene, speaking with one voice.
2021-2025 Member States




Promote and strengthen dialogue with and involvement of civil society in implementation, evaluation 
and providing input to the development of drug policies at Member State, EU and international levels.
2021-2025 Member States
Council of the EU
European Commission
EEAS
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ANNEX I 
Overarching indicators for the EU Drugs Action Plan 2021-2025 (1)
1) Developments in targeting high-risk organised crime groups: indicator based on cases reports and available 
statistical information on operations to disrupt high-risk organised crime groups targeting the EU, including review of 
major assets recovery operations and financial investigations and significant developments in cross border 
cooperation. (Sources Europol, European Commission, Member States, EMCDDA)
2) Trends in drug-related organised crime, corruption, intimidation and gang violence: indicator based on a 
summary of available structured data sources collected using a common methodology, case reports and expert 
opinion. (Sources: Europol, EMCDDA, Member States, European Commission)
3) Drug Markets Dashboard: Market Trends by market level in: number and quantities of seized illicit drugs; number of 
drug production labs seized; number of drug production related offences, drug prices and purity/dose (by market level 
where possible); data from other relevant information sources sensitive to understanding differences in drug 
availability, content and form, at different levels of the drug market where these are available; trends in the availability 
and use of precursors and other chemicals required for drug production; trends and developments in the use of the 
darknet and other digital-facilitated means for drug sales. (Sources: EMCDDA; Europol, European Commission, 
Member States)
4) Impact on communities: indicator measuring through two Eurobarometer studies (2021 and 2025) and, if available, 
other relevant national or EU-level data sources, perceptions of how drugs, their availability and the operation of drug 
markets impact on public health, safety and the security of communities, including drug-related violence and 
intimidation. (Sources: European Commission, Member States)
5) Health Dashboard: EU-level reporting on the health impact of drug use. Trends in drug related morbidity and 
mortality. Providing a summary analysis of the most recent available data from both established and developing 
sources on: trends in drug-related hospital emergencies, drug-related deaths, infectious diseases and associated health 
problems, including injecting drug use and other high-risk drug use behaviours, as well as mental health issues related 
to drug use, if data available. (Sources: EMCDDA, Member States)
6) Prevalence and patterns of drug use: indicator of trends from surveys of the general population who have used 
drugs (recently and ever) and from youth or school surveys on drug use (last year and ever) and the age of first drug 
initiation, and information on prevalence and patterns of drug use from other important subpopulations where 
available. (Sources: EMCDDA, ESPAD, HBSC, Member States)
7) Reducing Harm Dashboard: indicator of measures of availability of evidence-based prevention, treatment, harm 
reduction services, and alternatives to coercive sanctions (2) for drug-using offenders. Availability and coverage of 
opioid agonist treatment, availability of needle and syringe programmes and coverage of HCV, HIV and HBV testing 
and treatment for people who inject drugs. (Sources: EMCDDA, Member States)
(1) These indicators will be informed by statistical and other routine sources of information collected as part of ongoing efforts to monitor 
and respond to drug use in Europe and provide the most comprehensive set of EU-level resources to support the monitoring and 
evaluation of the EU Drugs Strategy 2021-2025 and EU Drugs Action Plan 2021-2025. Whilst the most up-to-date information 
available will be used, the data available will not necessarily correspond directly with the 2021-2025 period. Even though routine 
sources will be used whenever possible, some additional data collection exercises may be required to support the reporting of some of 
the indicators listed here. Therefore, they support a comprehensive evaluation and facilitate the assessment of the effectiveness, 
efficiency, relevance, coherence and EU added value of the Strategy and its Action Plan.
(2) The term ‘alternatives to coercive sanctions’ could, according to the national legislation of the Member States, also refer to alternatives 
that are used instead of or alongside the traditional criminal justice measures for drug-using offenders (see Council conclusions: 
Promoting the use of alternatives to coercive sanctions for drug using offenders, 8 March 2018.
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8) Trends and developments in NPS: indicator from Early Warning System on the appearance of and harm caused by 
new psychoactive substances, derived from reporting to the Early Warning System and Risk Assessment exercises on 
new psychoactive substances. (Sources: EMCDDA, Europol, Member States, European Commission)
9) Emerging Threats Dashboard: indicator that highlights potential emerging threats based on the triangulation of data 
from more timely and forward-looking sources (where available) including for example, levels of drug volumes 
consumed in community/cities from waste water analysis, web surveys, forensic, toxicological reporting, etc. 
(Sources: EMCDDA, Member States)
10) Responding to drug use in prison: indicator on the availability and coverage of responses to address the issue of 
drugs use in custodial settings including an assessment of the extent to which a comprehensive and balanced 
approach to responding to drug use exists in custodial settings. (Sources: EMCDDA, Member States)
11) Meeting commitments of the Sustainable Development Goals: indicator of progress made in relation to the 2030 
Agenda for Sustainable Development Goals (Eurostat report on the progress made towards achieving the SDGs 
relevant to drug issues).(Sources: Eurostat, European Commission)
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ANNEX II 
Glossary of acronyms
AIDS Acquired immunodeficiency syndrome
CEPOL European Union Agency for Law Enforcement Training
COSI Council of the European Union — Standing Committee on Operational Cooperation on 
Internal Security
COVID-19 Coronavirus Disease 2019
EDPQ European Drug Prevention Quality Standards
EEAS European External Action Service
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform Against Criminal Threats
ESPAD European School Survey Project on Alcohol and Other Drugs
EU European Union
EU SOCTA European Union Serious and Organised Crime Threat Assessment
EUCPN European Crime Prevention Network
EUPC European Prevention Curriculum
EUROJUST European Union Agency for Criminal Justice Cooperation
EUROPOL European Union Agency for Law Enforcement Cooperation
EUROSTAT Statistical Office of the European Union
FIUs Financial Intelligence Units
FRONTEX European Border and Coast Guard Agency
HBSC Health Behaviour in School-aged Children survey
HBV Hepatitis B virus
HCV Hepatitis C virus
HDG Council of the European Union — Horizontal Working Party on Drugs
HIV Human immunodeficiency virus
INCB International Narcotics Control Board
JHA Justice and Home Affairs
MAOC-N Maritime Analysis and Operation Centre - Narcotics
NPS New psychoactive substances
OECD Organisation for Economic Co-operation and Development
OECD-DAC OECD-Development Assistance Committee
REITOX Réseau Européen d’Information sur les Drogues et les Toxicomanies (European information 
network on drugs and drug addiction)
SDGs Sustainable Development Goals
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SIENA Secure Information Exchange Network Application
SOCTA Serious and Organised Crime Threat Assessment
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNGASS United Nations General Assembly Special Session on the World Drug Problem
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
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